Journal of Gastric Cancer

The Korean Gastric Cancer Association (대한위암학회)
권호 표지
DOI QR코드

DOI QR Code

Effect of Early Adjuvant Chemotherapy on Survival of Advanced Gastric Cancer Patients: a Propensity Score-matched Analysis

  • Lee, Yoontaek (Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Min, Sa-Hong (Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Park, Ki Bum (Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Park, Young Suk (Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Kim, Ji-Won (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Ahn, Sang-Hoon (Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Kim, Jin Won (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Park, Do Joong (Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Lee, Keun-Wook (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Kim, Hyung-Ho (Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine)
  • Received : 2018.01.31
  • Accepted : 2018.03.13
  • Published : 2018.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Generally, adjuvant chemotherapy (AC) should be initiated as soon as possible after surgery to eradicate microscopic cancer cells. In this study, we investigated the effect of early AC on the survival of stage II/III gastric cancer patients. Materials and Methods: Four hundred sixty patients who received AC (S-1 or XELOX) for pathologic stage II/III gastric cancer at Seoul National University Bundang Hospital between January 2008 and December 2014 were included. Patients were divided into 2 groups: early AC administration (within 4 weeks) and late AC administration (more than 4 weeks). Patients in the early AC group (n=174) were matched 1:1 with patients in the late AC group (n=174) by propensity scoring to adjust for clinical differences. Three-year relapse-free survival (RFS) was evaluated according to the timing of AC. Results: Three-year RFS was 98.1% in stage IIA (n=109), 85.0% in stage IIB (n=83), 87.4% in stage IIIA (n=96), 83.5% in stage IIIB (n=91), and 62.5% in stage IIIC (n=81). After propensity score matching, RFS was similar between early and late AC groups (hazard ratio [HR],1.04; 95% confidence interval [CI], 0.62-1.74; P=0.889). Pathologic stage and histological type were independent prognostic factors of RFS (HR, 2.05; 95% CI, 1.06-3.96; P=0.033 and HR, 2.61; 95% CI, 1.42-4.80; P=0.002, respectively). Conclusions: Early initiation of AC within 4 weeks does not affect survival rates in stage II/III gastric cancer.

Keywords

References

  1. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20. https://doi.org/10.1056/NEJMoa055531
  2. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-730. https://doi.org/10.1056/NEJMoa010187
  3. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012;379:315-321. https://doi.org/10.1016/S0140-6736(11)61873-4
  4. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-1820. https://doi.org/10.1056/NEJMoa072252
  5. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 2017;20:1-19.
  6. Park HS, Jung M, Kim HS, Kim HI, An JY, Cheong JH, et al. Proper timing of adjuvant chemotherapy affects survival in patients with stage 2 and 3 gastric cancer. Ann Surg Oncol 2015;22:224-231. https://doi.org/10.1245/s10434-014-3949-2
  7. Greenleaf EK, Kulaylat AN, Hollenbeak CS, Almhanna K, Wong J. Timing of adjuvant chemotherapy and impact on survival for resected gastric cancer. Ann Surg Oncol 2016;23:4203-4213. https://doi.org/10.1245/s10434-016-5464-0
  8. Di Bartolomeo M, Pietrantonio F, Rulli E, Poli D, Berenato R, Caporale M, et al. Impact on survival of timing and duration of adjuvant chemotherapy in radically resected gastric cancer. Tumori 2016;102:e15-e19. https://doi.org/10.5301/tj.5000480
  9. Kitano S, Iso Y, Moriyama M, Sugimachi K. Laparoscopy-assisted Billroth I gastrectomy. Surg Laparosc Endosc 1994;4:146-148.
  10. Kim HH, Hyung WJ, Cho GS, Kim MC, Han SU, Kim W, et al. Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interim report--a phase III multicenter, prospective, randomized Trial (KLASS Trial). Ann Surg 2010;251:417-420. https://doi.org/10.1097/SLA.0b013e3181cc8f6b
  11. Tokunaga M, Tanizawa Y, Bando E, Kawamura T, Terashima M. Poor survival rate in patients with postoperative intra-abdominal infectious complications following curative gastrectomy for gastric cancer. Ann Surg Oncol 2013;20:1575-1583. https://doi.org/10.1245/s10434-012-2720-9
  12. Croome KP, Farnell MB, Que FG, Reid-Lombardo KM, Truty MJ, Nagorney DM, et al. Total laparoscopic pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: oncologic advantages over open approaches? Ann Surg 2014;260:633-638.
  13. Malietzis G, Mughal A, Currie AC, Anyamene N, Kennedy RH, Athanasiou T, et al. Factors implicated for delay of adjuvant chemotherapy in colorectal cancer: a meta-analysis of observational studies. Ann Surg Oncol 2015;22:3793-3802. https://doi.org/10.1245/s10434-015-4479-2
  14. Kaito A, Kinoshita T, Shitara K, Shibasaki H, Nishida T. Timing of initiation of adjuvant chemotherapy for gastric cancer: a case-matched comparison study of laparoscopic vs. open surgery. Eur J Surg Oncol 2017;43:801-807. https://doi.org/10.1016/j.ejso.2017.01.008
  15. Ho DE, Imai K, King G, Stuart EA. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw 2011;42:1-28.
  16. Colleoni M, Bonetti M, Coates AS, Castiglione-Gertsch M, Gelber RD, Price K, et al. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. J Clin Oncol 2000;18:584-590.
  17. Biagi JJ, Raphael MJ, Mackillop WJ, Kong W, King WD, Booth CM. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. JAMA 2011;305:2335-2342. https://doi.org/10.1001/jama.2011.749
  18. Des Guetz G, Nicolas P, Perret GY, Morere JF, Uzzan B. Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis. Eur J Cancer 2010;46:1049-1055. https://doi.org/10.1016/j.ejca.2010.01.020
  19. dos Santos LV, Faria TM, Lima AB, Abdalla KC, de Moraes ED, Cruz MR, et al. Timing of adjuvant chemotherapy in colorectal cancer. Colorectal Dis 2016;18:871-876. https://doi.org/10.1111/codi.13306
  20. Arrington AK. Timing of chemotherapy and survival in patients with resectable gastric adenocarcinoma. World J Gastrointest Surg 2013;5:321-328. https://doi.org/10.4240/wjgs.v5.i12.321
  21. Kang SY, Ahn MS, Song GW, Choi YW, Lee HW, Jeong SH, et al. Does the timing of adjuvant chemotherapy for gastric cancer influence patient outcome? Acta Oncol 2015;54:1231-1234. https://doi.org/10.3109/0284186X.2014.1000467
  22. Yamamoto M, Sakaguchi Y, Kinjo N, Yamaguchi S, Egashira A, Minami K, et al. S-1 adjuvant chemotherapy earlier after surgery clinically correlates with prognostic factors for advanced gastric cancer. Ann Surg Oncol 2016;23:546-551.
  23. Fujitani K, Kurokawa Y, Takeno A, Endoh S, Ohmori T, Fujita J, et al. Time to initiation or duration of S-1 adjuvant chemotherapy; which really impacts on survival in stage II and III gastric cancer? Gastric Cancer 2017. doi: 10.1007/s10120-017-0767-9 [In press].

Cited by

  1. Role of circular RNAs in gastric cancer: Recent advances and prospects vol.11, pp.6, 2019, https://doi.org/10.4251/wjgo.v11.i6.459
  2. Delay in initiation of postoperative adjuvant chemotherapy with S-1 monotherapy and prognosis for gastric cancer patients: analysis of a multi-institutional dataset vol.22, pp.6, 2018, https://doi.org/10.1007/s10120-019-00961-9
  3. Optimal time interval from surgery to adjuvant chemotherapy in gastric cancer vol.20, pp.4, 2020, https://doi.org/10.3892/ol.2020.11893